[Defibrotide and heparin in the prevention of deep venous thromboses. A controlled study].
Forty-one surgical patients at risk of deep venous thrombosis (DVT) were treated with defibrotide (400 mg/b.i.d./i.v.) or with heparin (5000 UI/t.i.d./s.c.). Neither DVT nor pulmonary embolism was evidenced. In the heparin group the healing rate was longer and during the first three days bleeding from the surgical wound was more pronounced. In particular one patient of the heparin group had to interrupt the treatment for haemorrhage.
Villani
L G
LG
Istituto di Patologia Speciale Chirurgica, Università di Parma.
Dalla Valle
R
R
Rubini
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D004361:Drug Tolerance; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D013924:Thrombophlebitis / Q000453:epidemiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D006493:Heparin
Defibrotide ed eparina nella profilassi delle trombosi venose profonde. Studio controllato.